Vapotherm(R) Announces Validation of U.S. Patent

    STEVENSVILLE, Md., Jan. 22 /PRNewswire-USNewswire/ -- Vapotherm, the
 global leader in High Flow Oxygen Therapy products, announced today that
 U.S. patent rights have been validated for an apparatus used in the
 delivery tube technology for respiratory tract therapy. Reinforcing
 Vapotherm's principal role in the industry, the U.S. Patent No. 7,314,046
 B2 has been granted through 2022 and provides Vapotherm the right to
 prevent or exclude other companies from making, using, selling, or offering
 to sell or import the invention.
 
 
 
     The triple lumen design is the vital component for Vapotherm products
 as it helps deliver humidified air to the respiratory tract of patients.
 Used throughout all Vapotherm products, including the 2000i and the
 recently introduced Precision Flow(TM), the apparatus allows Vapotherm to
 maintain the conditioned breathing gases to the patient and thus aid with
 respiratory tract therapy and treatment.
 
 
 
     "Our patient delivery circuit design is unique in the field and
 provides Vapotherm with a competitive advantage through the delivery of
 optimally conditioned breathing gases all the way to the patient, whereas
 conventional approaches can result in significant temperature and humidity
 loss," said William Niland, Chairman and Chief Business Development Officer
 at Vapotherm.
 
 
 
     Vapotherm, Inc. is a privately held manufacturer of respiratory care
 devices for hospitals and home care use based in Stevensville, Maryland.
 The Company is dedicated to the development of innovative, noninvasive
 technologies for respiratory therapy, especially for the treatment of
 chronic lung and acute breathing disorders. For more information, visit
 http://www.vtherm.com.
 
 
 
     CONTACT:
 
     Amy Elias/Brian Johnson
 
     Profiles, Inc.
 
     410-243-3790
 
     amy@profilespr.com
 
     brian@profilespr.com
 
 
 
 
 
 
 
 
 

SOURCE Vapotherm, Inc.